CFO Mark Livingston Trims 2,139 Shares of Progyny Amid Steady 19‑% Weekly Rally

Insider Selling at Progyny: What It Means for Investors

Progyny’s chief financial officer, Mark S. Livingston, sold 2,139 shares on November 4, 2026, under a Rule 10b‑5‑1 trading plan that began on May 28. The shares were disposed of at roughly $30 per share—slightly below the close of $34.37—while the company’s stock was riding a 19‑percent weekly rally and a 26‑percent monthly gain. The sale comes amid a flurry of insider activity: the CFO has been systematically trimming his stake over the past year, selling between 224 and 2,532 shares each month, and most recently, 1,532 shares in early September.

Investor Take‑away Frequent, incremental sales by a senior executive can raise red flags for price-sensitive investors. However, the CFO’s trades are executed through a pre‑established 10b‑5‑1 plan, which is designed to mitigate insider‑trading concerns by locking in a schedule of sales. The plan’s expiration in 2027, combined with the recent sell‑off, suggests the CFO is gradually liquidating a portion of his holdings rather than reacting to a sudden market view. In a company that reported record Q3 earnings and a robust client‑retention rate, the CFO’s selling appears to be more about portfolio diversification than a bearish outlook on Progyny’s growth trajectory.

Implications for Progyny’s Future Progyny’s fundamentals remain strong: a 47‑percent year‑to‑date gain, a 27‑point P/E ratio, and a market cap of $2.3 billion. The CFO’s gradual divestiture may signal confidence in the company’s long‑term prospects, especially given the recent surge in new covered lives and a near‑complete retention rate. That said, the high social‑media buzz—almost 400 % above average—combined with a slight price dip could foreshadow short‑term volatility. Investors should monitor whether the CFO’s sales coincide with any earnings guidance or strategic shifts that might influence share price.

Mark S. Livingston: A Transaction Profile Livingston’s insider trading history is dominated by sales, with no recorded purchases in the last 18 months. He sold a total of 5,000 shares in September alone, a spike that followed a series of smaller monthly trades. His average sale price has trended upward from $17 in March to $30 in November, reflecting a gradual appreciation of the stock over time. Unlike other executives at Progyny—who have balanced buys and sells—Livingston’s pattern is consistent with a “sell‑to‑realize” strategy, likely motivated by tax planning or portfolio rebalancing rather than a signal of internal uncertainty.

Bottom Line While the CFO’s recent sale may prompt caution for short‑term traders, the broader context—solid earnings, a robust trading plan, and a gradual, systematic selling pattern—suggests that insider activity is more procedural than pessimistic. Investors can view the CFO’s divestiture as a normal part of executive portfolio management, while remaining alert to any forthcoming corporate developments that could alter the company’s growth narrative.